Micro Text Module #3 with downloadable slides

TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer

Share

Program Content

Activities

  • Safety of ADCs in MBC: Module
    Optimizing Outcomes and Quality of Life for Patients With Advanced Breast Cancer Through Effective Management of ADC-Associated Toxicities
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 07, 2024

    Expires: February 06, 2025

  • Safety of ADCs in MBC: Slides
    Optimizing Outcomes and Quality of Life for Patients With Advanced Breast Cancer Through Effective Management of ADC-Associated Toxicities
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 07, 2024

Faculty

cover img faculity

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.